Related Experiment Videos
Cost incentives for peripheral angioplasty
Insights
Peripheral vascular disease patients treated with bypass surgery incur significantly longer hospital stays and higher costs compared to percutaneous transluminal angioplasty (PTA). PTA is recommended as the preferred treatment option for medical and financial benefits.
Area of Science:
- Vascular Surgery
- Health Economics
- Interventional Cardiology
Background:
- Peripheral vascular disease (PVD) presents significant treatment challenges.
- Bypass surgery and percutaneous transluminal angioplasty (PTA) are common PVD interventions.
- Understanding the economic impact of these treatments is crucial for healthcare providers.
Purpose of the Study:
- To compare hospital costs and length of stay for PVD patients treated with bypass versus PTA.
- To evaluate the financial implications of each treatment modality in relation to reimbursement systems.
Main Methods:
- Retrospective analysis of 86 PVD patients.
- Comparison of length of stay and total hospital charges between bypass and PTA groups.
- Analysis of costs relative to diagnosis-related groups (DRGs) and Federal Prospective Payment System reimbursement.
Main Results:
- Bypass surgery resulted in an average length of stay 4-4.5 times longer than PTA.
- Total hospital charges for bypass were 3-3.7 times greater than for PTA.
- Significant cost disparities exist between the two treatment methods.
Conclusions:
- Percutaneous transluminal angioplasty (PTA) is a more cost-effective treatment for peripheral vascular disease.
- PTA offers considerable medical and financial advantages over bypass surgery for appropriately selected patients.
- Treatment choice should consider both clinical efficacy and economic impact.
Abstract:
Hospital costs and length of stay for 86 patients with peripheral vascular disease treated by bypass or percutaneous transluminal angioplasty (PTA) were assessed. The length of stay averaged 4-4.5 times longer, and the total hospital charge was 3-3.7 times greater, for bypass than for PTA. These charges are discussed in relation to current diagnosis-related groups (DRGs) and the allowed reimbursement from the Federal Prospective Payment System. In appropriately selected patients with peripheral vascular disease, PTA should be the treatment of choice from both medical and financial points of view.